Association of Lipoprotein-associated phospholipase A2 activity with components of the metabolic syndrome in apparently healthy boys

Autores
Hirschler, Valeria; Meroño, Tomás; Maccallini, Gustavo; Gomez Rosso, Leonardo Adrián; Aranda, Claudio; Brites, Fernando Daniel
Año de publicación
2011
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Abstract: Background: Lipoprotein-associated phospholipase A2 (Lp-PLA2) has been proposed as a biomarker of risk of cardiovascular disease (CVD). Objective: To determine the association between Lp-PLA2 activity and BMI, insulin-resistance, components of the metabolic syndrome (MS), and lifestyle behaviors in healthy adolescent boys. Methods: Data were collected cross-sectionally from 164 adolescents from an amateur rugby club. BMI, blood pressure (BP), Tanner stages, glucose, insulin, lipids, and Lp-PLA2 activity were measured. Questionnaires for lifestyle behaviors were completed. Results: Approximately 26% of the adolescents were obese and 23% overweight. There was a univariate association between Lp-PLA2 and BMI (r=0.16;p=0.042), triglycerides (r=0.26;p=0.001), LDL-C (r=0.46;p<0.001), apo B (r=0.55;p<0.001), whereas waist circumference, BP, glucose, HOMA-IR, and HDL-C were not correlated. None of the lifestyle behaviors were significantly correlated with Lp-PLA2. In order to analyze Lp-PLA2 association with known CVD risk conditions, adolescents were categorized according to overweight/obesity and to the presence of metabolic syndrome. Conversely, as it was for LDL-C and apo B concentration, Lp-PLA2 activity was not higher in adolescents with obesity. Multiple regression analysis showed that apo B was significantly associated with Lp-PLA2 adjusted for age, BMI, triglyc-erides and LDL-C (R2=0.32). Conclusion: Lp-PLA2 activity was only associated with apo B adjusted for several confounding variables, suggesting that its clinical utility to identify individuals at risk for CVD does not surpass LDL-C and apo B in healthy adolescents. As plaque morphology may change with age, associations of Lp-PLA2 with CVD may likewise vary with age.
Fil: Hirschler, Valeria. Gobierno de la Ciudad Autónoma de Buenos Aires. Hospital General de Agudos Carlos Durand; Argentina
Fil: Meroño, Tomás. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Fisiopatología y Bioquímica Clínica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Maccallini, Gustavo. Gobierno de la Ciudad Autónoma de Buenos Aires. Hospital General de Agudos Carlos Durand; Argentina
Fil: Gomez Rosso, Leonardo Adrián. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Fisiopatología y Bioquímica Clínica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Aranda, Claudio. Gobierno de la Ciudad Autónoma de Buenos Aires. Hospital General de Agudos Carlos Durand; Argentina
Fil: Brites, Fernando Daniel. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Fisiopatología y Bioquímica Clínica; Argentina
Materia
ADOLESCENTS
APO B
ATHEROSCLEROSIS
CARDIOVASCULAR DISEASE
CETP
CHILDREN
INSULIN RESISTANCE
LIPOPROTEIN PROFILE
LP-PLA2
METABOLIC SYNDROME
OBESITY
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/113428
Acceder
id CONICETDig_ed65a56bca7760c337c2942978ff0ccb
oai_identifier_str oai:ri.conicet.gov.ar:11336/113428
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Association of Lipoprotein-associated phospholipase A2 activity with components of the metabolic syndrome in apparently healthy boysHirschler, ValeriaMeroño, TomásMaccallini, GustavoGomez Rosso, Leonardo AdriánAranda, ClaudioBrites, Fernando DanielADOLESCENTSAPO BATHEROSCLEROSISCARDIOVASCULAR DISEASECETPCHILDRENINSULIN RESISTANCELIPOPROTEIN PROFILELP-PLA2METABOLIC SYNDROMEOBESITYhttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3Abstract: Background: Lipoprotein-associated phospholipase A2 (Lp-PLA2) has been proposed as a biomarker of risk of cardiovascular disease (CVD). Objective: To determine the association between Lp-PLA2 activity and BMI, insulin-resistance, components of the metabolic syndrome (MS), and lifestyle behaviors in healthy adolescent boys. Methods: Data were collected cross-sectionally from 164 adolescents from an amateur rugby club. BMI, blood pressure (BP), Tanner stages, glucose, insulin, lipids, and Lp-PLA2 activity were measured. Questionnaires for lifestyle behaviors were completed. Results: Approximately 26% of the adolescents were obese and 23% overweight. There was a univariate association between Lp-PLA2 and BMI (r=0.16;p=0.042), triglycerides (r=0.26;p=0.001), LDL-C (r=0.46;p<0.001), apo B (r=0.55;p<0.001), whereas waist circumference, BP, glucose, HOMA-IR, and HDL-C were not correlated. None of the lifestyle behaviors were significantly correlated with Lp-PLA2. In order to analyze Lp-PLA2 association with known CVD risk conditions, adolescents were categorized according to overweight/obesity and to the presence of metabolic syndrome. Conversely, as it was for LDL-C and apo B concentration, Lp-PLA2 activity was not higher in adolescents with obesity. Multiple regression analysis showed that apo B was significantly associated with Lp-PLA2 adjusted for age, BMI, triglyc-erides and LDL-C (R2=0.32). Conclusion: Lp-PLA2 activity was only associated with apo B adjusted for several confounding variables, suggesting that its clinical utility to identify individuals at risk for CVD does not surpass LDL-C and apo B in healthy adolescents. As plaque morphology may change with age, associations of Lp-PLA2 with CVD may likewise vary with age.Fil: Hirschler, Valeria. Gobierno de la Ciudad Autónoma de Buenos Aires. Hospital General de Agudos Carlos Durand; ArgentinaFil: Meroño, Tomás. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Fisiopatología y Bioquímica Clínica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Maccallini, Gustavo. Gobierno de la Ciudad Autónoma de Buenos Aires. Hospital General de Agudos Carlos Durand; ArgentinaFil: Gomez Rosso, Leonardo Adrián. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Fisiopatología y Bioquímica Clínica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Aranda, Claudio. Gobierno de la Ciudad Autónoma de Buenos Aires. Hospital General de Agudos Carlos Durand; ArgentinaFil: Brites, Fernando Daniel. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Fisiopatología y Bioquímica Clínica; ArgentinaBentham Science Publishers2011-04info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/113428Hirschler, Valeria; Meroño, Tomás; Maccallini, Gustavo; Gomez Rosso, Leonardo Adrián; Aranda, Claudio; et al.; Association of Lipoprotein-associated phospholipase A2 activity with components of the metabolic syndrome in apparently healthy boys; Bentham Science Publishers; Cardiovascular and Hematological Agents in Medicinal Chemistry; 9; 2; 4-2011; 78-831871-52571875-6182CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.2174/187152511796196542info:eu-repo/semantics/altIdentifier/url/https://www.eurekaselect.com/74546/articleinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T10:11:15Zoai:ri.conicet.gov.ar:11336/113428instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 10:11:16.45CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Association of Lipoprotein-associated phospholipase A2 activity with components of the metabolic syndrome in apparently healthy boys
title Association of Lipoprotein-associated phospholipase A2 activity with components of the metabolic syndrome in apparently healthy boys
spellingShingle Association of Lipoprotein-associated phospholipase A2 activity with components of the metabolic syndrome in apparently healthy boys
Hirschler, Valeria
ADOLESCENTS
APO B
ATHEROSCLEROSIS
CARDIOVASCULAR DISEASE
CETP
CHILDREN
INSULIN RESISTANCE
LIPOPROTEIN PROFILE
LP-PLA2
METABOLIC SYNDROME
OBESITY
title_short Association of Lipoprotein-associated phospholipase A2 activity with components of the metabolic syndrome in apparently healthy boys
title_full Association of Lipoprotein-associated phospholipase A2 activity with components of the metabolic syndrome in apparently healthy boys
title_fullStr Association of Lipoprotein-associated phospholipase A2 activity with components of the metabolic syndrome in apparently healthy boys
title_full_unstemmed Association of Lipoprotein-associated phospholipase A2 activity with components of the metabolic syndrome in apparently healthy boys
title_sort Association of Lipoprotein-associated phospholipase A2 activity with components of the metabolic syndrome in apparently healthy boys
dc.creator.none.fl_str_mv Hirschler, Valeria
Meroño, Tomás
Maccallini, Gustavo
Gomez Rosso, Leonardo Adrián
Aranda, Claudio
Brites, Fernando Daniel
author Hirschler, Valeria
author_facet Hirschler, Valeria
Meroño, Tomás
Maccallini, Gustavo
Gomez Rosso, Leonardo Adrián
Aranda, Claudio
Brites, Fernando Daniel
author_role author
author2 Meroño, Tomás
Maccallini, Gustavo
Gomez Rosso, Leonardo Adrián
Aranda, Claudio
Brites, Fernando Daniel
author2_role author
author
author
author
author
dc.subject.none.fl_str_mv ADOLESCENTS
APO B
ATHEROSCLEROSIS
CARDIOVASCULAR DISEASE
CETP
CHILDREN
INSULIN RESISTANCE
LIPOPROTEIN PROFILE
LP-PLA2
METABOLIC SYNDROME
OBESITY
topic ADOLESCENTS
APO B
ATHEROSCLEROSIS
CARDIOVASCULAR DISEASE
CETP
CHILDREN
INSULIN RESISTANCE
LIPOPROTEIN PROFILE
LP-PLA2
METABOLIC SYNDROME
OBESITY
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.2
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Abstract: Background: Lipoprotein-associated phospholipase A2 (Lp-PLA2) has been proposed as a biomarker of risk of cardiovascular disease (CVD). Objective: To determine the association between Lp-PLA2 activity and BMI, insulin-resistance, components of the metabolic syndrome (MS), and lifestyle behaviors in healthy adolescent boys. Methods: Data were collected cross-sectionally from 164 adolescents from an amateur rugby club. BMI, blood pressure (BP), Tanner stages, glucose, insulin, lipids, and Lp-PLA2 activity were measured. Questionnaires for lifestyle behaviors were completed. Results: Approximately 26% of the adolescents were obese and 23% overweight. There was a univariate association between Lp-PLA2 and BMI (r=0.16;p=0.042), triglycerides (r=0.26;p=0.001), LDL-C (r=0.46;p<0.001), apo B (r=0.55;p<0.001), whereas waist circumference, BP, glucose, HOMA-IR, and HDL-C were not correlated. None of the lifestyle behaviors were significantly correlated with Lp-PLA2. In order to analyze Lp-PLA2 association with known CVD risk conditions, adolescents were categorized according to overweight/obesity and to the presence of metabolic syndrome. Conversely, as it was for LDL-C and apo B concentration, Lp-PLA2 activity was not higher in adolescents with obesity. Multiple regression analysis showed that apo B was significantly associated with Lp-PLA2 adjusted for age, BMI, triglyc-erides and LDL-C (R2=0.32). Conclusion: Lp-PLA2 activity was only associated with apo B adjusted for several confounding variables, suggesting that its clinical utility to identify individuals at risk for CVD does not surpass LDL-C and apo B in healthy adolescents. As plaque morphology may change with age, associations of Lp-PLA2 with CVD may likewise vary with age.
Fil: Hirschler, Valeria. Gobierno de la Ciudad Autónoma de Buenos Aires. Hospital General de Agudos Carlos Durand; Argentina
Fil: Meroño, Tomás. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Fisiopatología y Bioquímica Clínica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Maccallini, Gustavo. Gobierno de la Ciudad Autónoma de Buenos Aires. Hospital General de Agudos Carlos Durand; Argentina
Fil: Gomez Rosso, Leonardo Adrián. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Fisiopatología y Bioquímica Clínica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Aranda, Claudio. Gobierno de la Ciudad Autónoma de Buenos Aires. Hospital General de Agudos Carlos Durand; Argentina
Fil: Brites, Fernando Daniel. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Fisiopatología y Bioquímica Clínica; Argentina
description Abstract: Background: Lipoprotein-associated phospholipase A2 (Lp-PLA2) has been proposed as a biomarker of risk of cardiovascular disease (CVD). Objective: To determine the association between Lp-PLA2 activity and BMI, insulin-resistance, components of the metabolic syndrome (MS), and lifestyle behaviors in healthy adolescent boys. Methods: Data were collected cross-sectionally from 164 adolescents from an amateur rugby club. BMI, blood pressure (BP), Tanner stages, glucose, insulin, lipids, and Lp-PLA2 activity were measured. Questionnaires for lifestyle behaviors were completed. Results: Approximately 26% of the adolescents were obese and 23% overweight. There was a univariate association between Lp-PLA2 and BMI (r=0.16;p=0.042), triglycerides (r=0.26;p=0.001), LDL-C (r=0.46;p<0.001), apo B (r=0.55;p<0.001), whereas waist circumference, BP, glucose, HOMA-IR, and HDL-C were not correlated. None of the lifestyle behaviors were significantly correlated with Lp-PLA2. In order to analyze Lp-PLA2 association with known CVD risk conditions, adolescents were categorized according to overweight/obesity and to the presence of metabolic syndrome. Conversely, as it was for LDL-C and apo B concentration, Lp-PLA2 activity was not higher in adolescents with obesity. Multiple regression analysis showed that apo B was significantly associated with Lp-PLA2 adjusted for age, BMI, triglyc-erides and LDL-C (R2=0.32). Conclusion: Lp-PLA2 activity was only associated with apo B adjusted for several confounding variables, suggesting that its clinical utility to identify individuals at risk for CVD does not surpass LDL-C and apo B in healthy adolescents. As plaque morphology may change with age, associations of Lp-PLA2 with CVD may likewise vary with age.
publishDate 2011
dc.date.none.fl_str_mv 2011-04
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/113428
Hirschler, Valeria; Meroño, Tomás; Maccallini, Gustavo; Gomez Rosso, Leonardo Adrián; Aranda, Claudio; et al.; Association of Lipoprotein-associated phospholipase A2 activity with components of the metabolic syndrome in apparently healthy boys; Bentham Science Publishers; Cardiovascular and Hematological Agents in Medicinal Chemistry; 9; 2; 4-2011; 78-83
1871-5257
1875-6182
CONICET Digital
CONICET
url http://hdl.handle.net/11336/113428
identifier_str_mv Hirschler, Valeria; Meroño, Tomás; Maccallini, Gustavo; Gomez Rosso, Leonardo Adrián; Aranda, Claudio; et al.; Association of Lipoprotein-associated phospholipase A2 activity with components of the metabolic syndrome in apparently healthy boys; Bentham Science Publishers; Cardiovascular and Hematological Agents in Medicinal Chemistry; 9; 2; 4-2011; 78-83
1871-5257
1875-6182
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.2174/187152511796196542
info:eu-repo/semantics/altIdentifier/url/https://www.eurekaselect.com/74546/article
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv Bentham Science Publishers
publisher.none.fl_str_mv Bentham Science Publishers
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842270151548862464
score 13.13397

Publicaciones similares